EA200300222A1 - Лечение гепатита c с помощью тимозина, интерферона и рибавирина - Google Patents

Лечение гепатита c с помощью тимозина, интерферона и рибавирина

Info

Publication number
EA200300222A1
EA200300222A1 EA200300222A EA200300222A EA200300222A1 EA 200300222 A1 EA200300222 A1 EA 200300222A1 EA 200300222 A EA200300222 A EA 200300222A EA 200300222 A EA200300222 A EA 200300222A EA 200300222 A1 EA200300222 A1 EA 200300222A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hepatitis
interferon
effective amount
tymosin
ribavirin
Prior art date
Application number
EA200300222A
Other languages
English (en)
Other versions
EA007785B1 (ru
Inventor
Алфред Р. Рудолф
Original Assignee
Сайклоун Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сайклоун Фармасьютикалз, Инк. filed Critical Сайклоун Фармасьютикалз, Инк.
Publication of EA200300222A1 publication Critical patent/EA200300222A1/ru
Publication of EA007785B1 publication Critical patent/EA007785B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Abstract

В заявке описан способ и фармацевтическая композиция для лечения гепатита C, предусматривающий введение страдающему гепатитом C пациенту эффективного количества, по меньшей мере, одного тимозина или эффективного количества, по меньшей мере, одного фрагмента тимозина в сочетании с введением пациенту, страдающему гепатитом C, эффективного количества, по меньшей мере, одного интерферона, а также в сочетании с введением пациенту эффективного количества антивирусного агента.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200300222A 2000-08-07 2001-08-06 Способ лечения гепатита с с помощью тимозина, интерферона и рибавирина EA007785B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22331700P 2000-08-07 2000-08-07
PCT/US2001/041550 WO2002011749A1 (en) 2000-08-07 2001-08-06 Treatment of hepatitis c with thymosin, interferon and ribavirin

Publications (2)

Publication Number Publication Date
EA200300222A1 true EA200300222A1 (ru) 2003-08-28
EA007785B1 EA007785B1 (ru) 2007-02-27

Family

ID=22835988

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300222A EA007785B1 (ru) 2000-08-07 2001-08-06 Способ лечения гепатита с с помощью тимозина, интерферона и рибавирина

Country Status (18)

Country Link
EP (1) EP1311279B1 (ru)
KR (1) KR100851861B1 (ru)
CN (1) CN1446096A (ru)
AT (1) ATE348628T1 (ru)
AU (2) AU2001283536B2 (ru)
BR (1) BR0113115A (ru)
CA (1) CA2418085A1 (ru)
CY (1) CY1106388T1 (ru)
DE (1) DE60125377T2 (ru)
DK (1) DK1311279T3 (ru)
EA (1) EA007785B1 (ru)
ES (1) ES2275711T3 (ru)
HK (1) HK1055689A1 (ru)
IL (1) IL154299A0 (ru)
MX (1) MXPA03001145A (ru)
NZ (1) NZ524579A (ru)
PT (1) PT1311279E (ru)
WO (1) WO2002011749A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2733518A1 (en) * 2008-08-06 2010-02-11 Sciclone Pharmaceuticals, Inc. Treatment or prevention of hepatitis c with immunomodulator compounds
CN102458470B (zh) 2009-05-08 2016-01-20 赛生制药有限公司 作为疫苗增强剂的α胸腺素肽
RU2473341C1 (ru) * 2011-08-02 2013-01-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Сибирский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО СибГМУ Минздравсоцразвития) Способ профилактики вертикальной передачи вирусов гепатитов в и с у беременных с реактивацией вирусов в третьем триместре

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW224053B (ru) * 1991-09-13 1994-05-21 Paul B Chretien
US5610054A (en) * 1992-05-14 1997-03-11 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecule targeted against Hepatitis C virus
US5849800A (en) * 1997-03-28 1998-12-15 The Penn State Research Foundation Use of amantadine for treatment of Hepatitis C
WO1999064016A1 (en) * 1998-06-08 1999-12-16 F. Hoffmann-La Roche Ag Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
CA2354536A1 (en) * 1998-12-18 2000-06-29 Schering Corporation Ribavirin-pegylated interferon alfa induction hcv combination therapy

Also Published As

Publication number Publication date
BR0113115A (pt) 2003-06-10
EP1311279B1 (en) 2006-12-20
KR100851861B1 (ko) 2008-08-13
EP1311279A1 (en) 2003-05-21
CY1106388T1 (el) 2011-10-12
DE60125377D1 (de) 2007-02-01
ATE348628T1 (de) 2007-01-15
EA007785B1 (ru) 2007-02-27
KR20030034129A (ko) 2003-05-01
PT1311279E (pt) 2007-03-30
DK1311279T3 (da) 2007-02-12
WO2002011749A1 (en) 2002-02-14
AU8353601A (en) 2002-02-18
IL154299A0 (en) 2003-09-17
ES2275711T3 (es) 2007-06-16
DE60125377T2 (de) 2007-09-27
MXPA03001145A (es) 2004-08-02
EP1311279A4 (en) 2004-08-11
AU2001283536B2 (en) 2005-09-01
CN1446096A (zh) 2003-10-01
HK1055689A1 (en) 2004-01-21
NZ524579A (en) 2004-06-25
CA2418085A1 (en) 2002-02-14

Similar Documents

Publication Publication Date Title
MY124091A (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
AR021876A1 (es) Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado
DE602004028841D1 (de) Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c
EA200201263A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ВИРУСОМ ГЕПАТИТА ДЕЛЬТА, С ИСПОЛЬЗОВАНИЕМ β-L-2'-ДЕЗОКСИНУКЛЕОЗИДОВ
EA200201279A1 (ru) Способы и композиции для лечения вирусного гепатита c
DK1003546T3 (da) Fremgangsmåde til behandling af patienter ramt af dissemineret sklerose ved anvendelse af konsensus interferon
DE60237721D1 (de) Kombinationstherapie mit omega-interferon zur behandlung von hepatitis c virus oder gelbfieber virus infektionen
BR9808221A (pt) Método de tratamento de tumor.
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
DE60123042D1 (de) L-fmau zur behandlung von hepatitis-delta-virus-infizierung
ZA991029B (en) Composition and methods for treatment of hiv infections.
PT1237562E (pt) Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas
EA200300222A1 (ru) Лечение гепатита c с помощью тимозина, интерферона и рибавирина
WO2002015664A3 (en) Methods of preventing or treating west nile virus and other infections
ATE332704T1 (de) Behandlung von hepatitis c mit thymosin und pegyliertem interferon
TR199801801T2 (xx) Madde k�t�ye kullan�m�n�n tedavisi.
MXPA05007901A (es) Terapia de combinacion para hcv.
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
EA199800822A1 (ru) Способ лечения избыточной агрессии
EA199800820A1 (ru) Способ лечения злоупотребления лекарственными средствами
EA199800818A1 (ru) Способ лечения бессонницы
ECSP993003A (es) Uso de peg - ifn -alpha y ribavirina para el tratamiento de hepatitis c cronica

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU